Annual report
2413.TEDINET S100YJ25
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥351.4bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥284.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥238.9bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥230.8bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥73.5bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥63.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥76.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥64.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥68.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥74.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥49.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥45.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥49.0bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥54.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥44.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥637.4bn | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥581.7bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥490.8bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥400.6bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥346.0bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥190.7bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥168.9bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥446.6bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥412.8bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥366.7bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥408.2bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥378.4bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥351.9bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥302.6bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥257.8bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥156.2bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥134.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥149.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥104.3bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥70.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥58.3bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥57.1bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥15.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥39.5bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.9bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥35.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥27.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥9.4bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥22.8bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥72.53 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.62 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥66.68 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥72.22 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.5 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.6 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥66.63 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥72.17 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥608.98 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥555.07 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥516.49 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥444.22 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 64.0% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.1% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 75.5% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.5% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.8% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 17.5% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 17,010 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 15,360 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,100 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 10,533 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 9,384 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥47.2bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥45.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥51.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥54.5bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥19.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥27.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥84.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥28.0bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥31.9bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥27.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥24.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥21.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥75.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥268.7bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥265.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥251.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥232.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥215.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥45.4bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥31.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥223.3bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥233.1bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥226.0bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥162.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥152.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥79.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥78.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥35.44 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.85 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.14 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥35.43 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.56 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥111.77 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.12 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥332.42 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥341.34 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥331.17 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥237.22 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 82.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 39.4% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 679,120,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,077,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 679,063,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,964,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 750 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 704 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 649 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 588 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 574 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 68
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥4.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| Career Solutionreportable segment | employees | at 2026-03-31 | 1061 pure |
| Career Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥22.8bn |
| Career Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥22.7bn |
| Career Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥75m |
| Career Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.9bn |
| Evidence Solutionreportable segment | employees | at 2026-03-31 | 2361 pure |
| Evidence Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥24.5bn |
| Evidence Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.4bn |
| Evidence Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥167m |
| Evidence Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 3407 pure |
| Medical Platformreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥107.8bn |
| Medical Platformreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥104.0bn |
| Medical Platformreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.8bn |
| Medical Platformreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥35.9bn |
| Overseasreportable segment | employees | at 2026-03-31 | 3065 pure |
| Overseasreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥86.9bn |
| Overseasreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥16m |
| Overseasreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥14.9bn |
| Patient Solutionreportable segment | employees | at 2026-03-31 | 1208 pure |
| Patient Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥56.9bn |
| Patient Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4m |
| Patient Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Site Solutionreportable segment | employees | at 2026-03-31 | 5740 pure |
| Site Solutionreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥54.4bn |
| Site Solutionreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥54.3bn |
| Site Solutionreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7m |
| Site Solutionreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥5.8bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥353.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥349.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥70.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.1bn |
| Career Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Career Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥32m |
| Career Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| Evidence Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥24.2bn |
| Evidence Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.0bn |
| Evidence Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥223m |
| Evidence Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Medical Platformreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.6bn |
| Medical Platformreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥88.2bn |
| Medical Platformreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Medical Platformreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥34.1bn |
| Overseasreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥80.6bn |
| Overseasreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥80.5bn |
| Overseasreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥64m |
| Overseasreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥14.7bn |
| Patient Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥21.9bn |
| Patient Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥824m |
| Site Solutionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥47.0bn |
| Site Solutionreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12m |
| Site Solutionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥286.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥282.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥65.1bn |
| Medical Platformreportable segment | employees | at 2026-03-31 | 658 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,852
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)医療・ヘルスケア分野におけるビジネス拡大のため※２ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)(株)オルツ 普通株式 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)医療・ヘルスケア分野におけるビジネス拡大のため※２ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)クリングルファーマ(株) | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)医療・ヘルスケア分野におけるビジネス拡大のため※２ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)(株)ケアネット | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)情報収集のため※２ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)エムスリーソリューションズ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)㈱イーウェル | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)エムスリーマーケティング㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)㈱日本アルトマーク | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | Original text (Japanese)㈱メディサイエンスプラニング | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | Original text (Japanese)メビックス㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | Original text (Japanese)ノイエス㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row8Member | Original text (Japanese)エムスリーキャリア㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row9Member | Original text (Japanese)㈱シーユーシー | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row10Member | Original text (Japanese)ソフィアメディ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | Original text (Japanese)㈱シーユーシー・ホスピス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | Original text (Japanese)㈱ノアコンツェル | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | Original text (Japanese)㈱エラン | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しています。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc and internal system to prepare consolidated financial statements etc fairly in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Consolidated statement of financial position IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of profit or loss IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes reporting entity consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes basis of preparation consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting estimates and judgements consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about products and services IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about geographical areas IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about major customers IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes business combinations consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes cash and cash equivalents consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes trade and other receivables consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |